ArticleEmerging microbes & infections2026
Loss of ribosomal protein RPL22 restricts African swine fever virus replication by inducing PERK-dependent ER stress.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV) is a large DNA virus that causes highly lethal disease in domestic pigs and wild boars, posing a significant threat to the global swine industry. The development of effective antivirals and vaccines is hindered by the complex structure of the virus and its sophisticated manipulation of host cellular processes. The inner envelope protein p54 is essential for multiple stages of the viral life cycle, including attachment, entry, and replication. In this study, we employed TurboID-based proximity labeling to systematically map the host protein interactome of ASFV p54. Our screen identified 257 potential host interacting partners. Among these, the interaction between p54 and the 60S ribosomal protein L22 (RPL22) was validated by co-immunoprecipitation and confocal microscopy. Functional studies using an RPL22-knockout (RPL22-KO) cell line revealed that RPL22 serves as a regulatory host factor for ASFV infection. Mechanistically, the loss of RPL22 significantly inhibited ASFV replication through the activation of the PERK signaling pathway. This finding was further substantiated by pharmacological intervention; activation of the ERS/PERK pathway using thapsigargin (Tg) or CCT020312 suppressed viral replication, whereas its inhibition with 4-phenylbutyric acid (4-PBA) or AMG-PERK 44 promoted replication. In conclusion, this study presents the first systematic interactome of ASFV p54 and reveals a novel mechanism by which the host factor RPL22 modulates ASFV replication via the ERS-PERK pathway. These findings offer new insights into ASFV-host interactions and identify the ERS pathway as a promising therapeutic target for the development of anti-ASFV strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.